Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury.

Perceptive Advisors seeded, incubated and launched LianBio in August with $70 million and exclusive rights in China and other major Asian markets outside of Japan to three programs from two of its portfolio companies: MyoKardia Inc. (NASDAQ:MYOK) and BridgeBio Pharma Inc. (NASDAQ:BBIO)...